更新于：2024-11-01

Baldness, Female Pattern

女性雄激素源性脱发

更新于：2024-11-01

基本信息

别名

Baldness, Female Pattern、Female Pattern Baldness、Female pattern alopecia

+ [9]

简介-

关联

项与女性雄激素源性脱发相关的药物

OMA-102

靶点-

作用机制-

在研机构

EMS SA (Brazil)

原研机构

EMS SA (Brazil)

在研适应症

女性雄激素源性脱发

非在研适应症-

最高研发阶段临床3期

首次获批国家/地区-

首次获批日期1800-01-20

ENERGI-F701

靶点

AMPK

作用机制

AMPK激动剂

在研机构-

原研机构

华安医学股份有限公司

在研适应症-

非在研适应症

女性雄激素源性脱发

最高研发阶段无进展

首次获批国家/地区-

首次获批日期1800-01-20

项与女性雄激素源性脱发相关的临床试验

NCT05824065 / Not yet recruiting临床3期

Phase III, National, Multicenter, Randomized, Double-Blind, Superiority Clinical Trial to Evaluate the Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss

The goal of this clinical trial is to evaluate the efficacy and safety of OMA102 1 mg and OMA102 2 mg versus placebo in the treatment of female pattern hair loss.

开始日期2025-01-01

申办/合作机构

EMS SA (Brazil)

NCT06501924 / Not yet recruiting临床3期

Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss

The primary objective of the study is to assess the safety and efficacy of DA-005 and DA-002 as a treatment for hair loss (androgenetic alopecia).

开始日期2024-11-15

申办/合作机构

Applied Biology, Inc.

[+2]

NCT06484881 / Withdrawn临床3期

Clinical Study of Probiotic Treatment for Androgenetic Alopecia

The primary objective of the study is to assess the efficacy of DA-001 as an oral supplement for treatment of female pattern hair loss.

开始日期2024-09-15

申办/合作机构

Applied Biology, Inc.

[+1]

100 项与女性雄激素源性脱发相关的临床结果

登录后查看更多信息

100 项与女性雄激素源性脱发相关的转化医学

登录后查看更多信息

0 项与女性雄激素源性脱发相关的专利（医药）

登录后查看更多信息

项与女性雄激素源性脱发相关的文献（医药）

2024-03-03·Expert Review of Endocrinology & Metabolism

An updated clinico-investigative approach to diagnosis of cutaneous hyperandrogenism in relation to adult female acne, female pattern alopecia & hirsutism a primer for dermatologists

Review

作者: Sehrawat, Manu ; Sardana, Kabir ; Khurana, Ananta ; Muddebihal, Aishwarya ; Bansal, Prekshi

INTRODUCTIONHyperandrogenism is a clinical state consequent to excess androgen production by the ovary, adrenals, or increased peripheral conversion of androgens. The varied manifestations of hyperandrogenism include seborrhea, acne, infertility, hirsutism, or overt virilization of which adult female acne, hirsutism, and female pattern hair loss are of clinical relevance to dermatologists.AREAS COVEREDWe limited our narrative review to literature published during period from 1 January 1985 to Dec 2022 and searched PubMed/MEDLINE, Web of Science (WOS), Scopus, and Embase databases with main search keywords were 'Hyperandrogenism,' 'Female,' 'Biochemical,' 'Dermatological', and 'Dermatology.' We detail the common etiological causes, nuances in interpretation of biochemical tests and imaging tools, followed by an algorithmic approach which can help avoid extensive tests and diagnose the common causes of hyperandrogenism.EXPERT OPINIONBased on current data, total testosterone, sex hormone binding globulin, DHEAS, prolactin, free androgen index, and peripheral androgenic metabolites like 3-alpha diol and androsterone glucuronide are ideal tests though not all are required in all patients. Abnormalities in these biochemical investigations may require radiological examination for further clarification. Total testosterone levels can help delineate broadly the varied causes of hyperandrogenism. Serum AMH could be used for defining PCOM in adults.

2024-02-01·Journal of the European Academy of Dermatology and Venereology

Female diffuse non‐cicatricial alopecia—The diagnostic value of trichoscopy

Letter

作者: Sechi, A. ; Sirtoli Marcondes, M. T. ; Iorizzo, M. ; Starace, M. ; Piraccini, B. M. ; Therianou, A.

2023-09-09·Cureus

Efficacy of Dr. SKS Hair Booster Serum in the Treatment of Female Pattern Alopecia in Patients With PCOS: An Open-Label, Non-randomized, Prospective Study

Article

作者: Khare, Stuti

Background Many patients with polycystic ovary syndrome (PCOS) exhibit female pattern hair loss (FPHL). A more advanced, efficient, and suitable therapeutic approach is required to effectively manage FPHL in patients with PCOS. Aim Dr. SKS Hair Booster Serum is composed of copper, niacinamide, hyaluronic acid, thiamine, riboflavin, and biotin; each of these constituents has demonstrated individual efficacy in promoting hair growth and enhancing hair quality. We hereby assess the effectiveness of this novel hair formulation in treating FPHL in PCOS. Methods This was an open-label, non-randomized, multicenter, prospective, large study with a wide range of age groups. The study involving 1,000 females aged 25-50 years, diagnosed with PCOS and having complaints of FPHL with Ludwig grades I and II. Each patient received a monthly session of Dr. SKS Hair Booster Serum, with 1 mL of serum administered through injection into the superficial layer (dermis) of the scalp using a tiny infusion via an insulin syringe, mesotherapy, or via a derma roller/derma pen. All the patients were subjected to standard global photography, video microscopic assessment (vellus hair counts, terminal hair counts, and hair shaft diameter), and a subject self-assessment questionnaire at baseline and six months after the treatment. Results After six months of the treatment, the hair shaft diameter, terminal hair counts, and hair growth rate were significantly increased than baseline (p≤0.0001), and a significant reduction was noted in vellus hair counts than baseline measurement (p<0.00001). These findings are suggestive of improved hair regrowth after the treatment. No adverse events were recorded during the study. Statistically significant improvements were observed in hair parameters (overall hair fall rate, hair texture, hair volume, and scalp itching) after six months of treatment than baseline. Conclusion Dr. SKS Hair Booster Serum has been shown to be an effective treatment for FPHL in patients with PCOS. This study marks the first investigation into the use of Dr. SKS Hair Booster Serum in patients with PCOS.